西藏药业：公司的新活素发明专利是指保护新活素制剂及其制备方法的专利，保护期限为2011年到2031年

Core Viewpoint - The company is addressing concerns regarding the patent expiration of its flagship product, Xinhuosu, which is set to expire in 2031, and the potential impact of generic drugs entering the market [2] Group 1: Patent and Market Protection - The invention patent for Xinhuosu covers the formulation and preparation method, with a protection period from 2011 to 2031 [2] - The five-year new drug monitoring protection period has already expired, allowing other companies to develop and market related products [2] Group 2: Competitive Landscape - Suzhou Landing Biological has received approval for its recombinant human brain natriuretic peptide injection, indicating increased competition in the market [2] Group 3: Strategic Response - The company plans to enhance collaboration with commercial partners to expand the number of medical institutions covered by Xinhuosu, which currently includes nearly 7,000 institutions [2] - An investment of several million yuan is planned for exploratory research in evidence-based medicine for Xinhuosu, alongside ongoing academic promotion and production assurance efforts [2]